Sanofi sells manufacturing site to Recipharm; Aptose buys rights to sell CrystalGenomics’ cancer drug in China

Sanofi is selling off its contract respiratory drug manufacturing site in the UK to Recipharm, which is picking up manufacturing capacity as well as new clients in the $60 million deal. The plant’s 450 staffers will switch to their new employer when the deal closes later this year.

→ San Diego’s Aptose Biosciences $APTO has expanded its licensing agreement with South Korea’s CrystalGenomics to sell the latter company’s drug CG-806 in China, Macau, and Hong Kong. Aptose is paying CrystalGenomics $3 million upfront, with a total deal value of $125 million including milestones and royalties. CG-806 is a small molecule being developed for the treatment of acute myeloid leukemia, B-cell malignancies, and additional blood cancers. Back in May, Aptose grabbed an exclusive license from CrystalGenomics to develop and commercialize CG-806 worldwide outside of China and Korea. This new deal extends that license agreement to include China.

→ Under pressure from investors over its lackluster performance, Allergan has now recruited Abbott Laboratories’ former EVP of finance, Thomas Freyman, to its board. Patrick O’Sullivan, meanwhile, is on his way out as the company continues with what it calls its “refreshment” process for the board.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 48,200+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Research Scientist - Immunology
Recursion Pharmaceuticals Salt Lake City, UT
Director of Operations
Atlas Venture Cambridge, MA

Visit Endpoints Careers ->